The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 04, 2025

Filed:

Feb. 12, 2020
Applicant:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Inventors:

Christos Kyratsous, Irvington, NY (US);

Chia-Yang Lin, Scarsdale, NY (US);

Andrew J. Murphy, Croton-on-Hudson, NY (US);

Brinda Prasad, Princeton, NJ (US);

Neil Stahl, Carmel, NY (US);

Assignee:

REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/12 (2006.01); A61K 39/00 (2006.01); A61P 31/04 (2006.01); A61P 31/16 (2006.01); C07K 16/10 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C07K 16/1271 (2013.01); A61K 39/00 (2013.01); A61P 31/04 (2018.01); A61P 31/16 (2018.01); C07K 16/1018 (2013.01); C07K 16/1214 (2013.01); C07K 16/2878 (2013.01); C07K 16/2887 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/734 (2013.01); C07K 2317/92 (2013.01);
Abstract

According to certain embodiments, the present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds a target antigen and a second antigen binding domain that binds a complement component. In certain embodiments, the bispecific antigen-binding molecules of the present disclosure are capable of binding to the target antigen with an ECof about 10 nM or less, and/or are capable of promoting complement deposition on the target antigen with an ECof about 10 nM. In certain embodiments, the bispecific antigen-binding molecules of the disclosure are useful for treating diseases in which inhibition or reduction of the growth of an infectious agent or cancer cell is desired and/or therapeutically beneficial.


Find Patent Forward Citations

Loading…